en · de · es
glossary-desk.peptides4800.com › Wiki › Tirzepatide Pharmacology And Development History — Background and Details

Tirzepatide Pharmacology And Development History — Background and Details

By Editorial Desk · published 2026-04-13 · last reviewed 2026-05-27 · Wiki

Everything below concerns 稳定性. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-05-27. Where a claim depends on a specific study, the study is described rather than over-claimed.

Tirzepatide Pharmacology and Development History

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

储存处理与检测方法

纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息:前者反映疏水性杂质,后者反映聚集体,质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异,属于需要逐案验证的问题。

质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持,单次测定不足以判定批次的稳定性。实验室之间方法转移时,色谱柱品牌与梯度差异常导致保留时间漂移,因此方法验证十分必要。

固体状态的 tirzepatide 通常以冻干粉形式保存,推荐在低温、避光、干燥条件下存放,常见区间为 2 至 8 摄氏度,长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出,从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。

Tirzepatide at a glance

PropertyValueNotes
Molecular classModified synthetic peptide39-residue backbone with non-natural residues
Receptor targetsGIP and GLP-1Dual incretin receptor agonist
Approximate molecular mass4,813 DaCalculated from the peptide sequence
Administration routeSubcutaneous injectionWeekly schedule in approved products
Albumin bindingPresentMediated by a C20 fatty diacid side chain

Dual Incretin Receptor Agonism

The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.

In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.

Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.

Related pages on this site

Molecular Background and Receptor Pharmacology

Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.

The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.

After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.

Notes from published material

Statistical Coupling Analysis (SCA) is a method used in bioinformatics to study how pairs of amino acids in a protein sequence evolve together. It analyzes a multiple sequence alignment (MSA), which is a display of the sequences of many related proteins arranged to highlight similarities and differences. SCA measures how much the amino acid makeup at one position in the protein changes when the amino acid makeup at another position is altered. This relationship is quantified as statistical coupling energy. A higher coupling energy indicates that the amino acids at both positions are more likely to have co-evolved and are therefore functionally or structurally linked. In simpler terms, it helps scientists understand which parts of a protein are working together and how they have changed over evolutionary time.

Israeli defense minister Yoav Gallant met with mayors and local council heads in Nahariya, northern Israel to discuss the threat of Hezbollah to northern residents. Gallant said that if diplomacy fails, Israel will use its military to force Hezbollah north of the Litani River. On 11 December, the mayor of the southern Lebanese village of Taybeh was killed in an Israeli airstrike. Two other Hezbollah fighters were killed by Israeli airstrikes and artillery shelling in Aitaroun, and three civilians were injured. Other airstrikes were carried out by the IAF, destroying five houses and damaging 17 others. Four batches of missiles fired from Lebanon towards northern Israel were intercepted by the Iron Dome defense system, while the Islamic Resistance claimed it attacked several Israeli sites. According to Israeli media, three soldiers were injured. Hezbollah and other militias attacked nine Israeli towns and military positions. Israeli war cabinet minister and former defense minister Benny Gantz discussed security in northern Israel in a phone call with US secretary of state Antony Blinken. Gantz said he conveyed that Hezbollah's heightened aggression and attacks mean that Israel must "remove" the threat from northern Israel. Gantz's statement singled out the Lebanese state, not just Hezbollah, and called for international pressure on Lebanon to stop attacks on its southern border. The Syrian Social Nationalist Party in Lebanon announced the death of one member of their military wing, the Eagles of the Whirlwind, on 15 December.

==== Front end ==== Waste from the front end of the nuclear fuel cycle is usually alpha-emitting waste from the extraction of uranium. It often contains radium and its decay products. Uranium dioxide (UO2) concentrate from mining is a thousand or so times as radioactive as the granite used in buildings. It is refined from yellowcake (U3O8), then converted to uranium hexafluoride gas (UF6). As a gas, it undergoes enrichment to increase the U-235 content from 0.7% to about 4.4% (LEU). It is then turned into a hard ceramic oxide (UO2) for assembly as reactor fuel elements. The main by-product of enrichment is depleted uranium (DU), principally the U-238 isotope, with a U-235 content of ~0.3%. It is stored, either as UF6 or as U3O8. Some is used in applications where its extremely high density makes it valuable such as anti-tank shells, and on at least one occasion even a sailboat keel. It is also used with plutonium for making mixed oxide fuel (MOX) and to dilute, or downblend, highly enriched uranium from weapons stockpiles which is now being redirected to become reactor fuel.

Sources: en.wikipedia.org

Background from the literature

== Prevalence and health effects == Lignans are the principal source of dietary phytoestrogens in typical Western diets, even though most research on phytoestrogen-rich diets has focused on soy isoflavones. Lignan's enterolignan products enterodiol and enterolactone have weak estrogenic activity, but they may also exert biological effects through non-estrogenic means. A 2021 review found that lignans have a positive effect on lipid profiles of patients with dyslipidemia related diseases. As of 2022, there is limited evidence that dietary intake of lignans is associated with a reduced cancer and cardiovascular disease risk.

=== N05CM Other hypnotics and sedatives === N05CM01 Methaqualone N05CM02 Clomethiazole N05CM03 Bromisoval N05CM04 Carbromal N05CM05 Scopolamine N05CM06 Propiomazine N05CM07 Triclofos N05CM08 Ethchlorvynol N05CM10 Hexapropymate N05CM11 Bromides N05CM12 Apronal N05CM13 Valnoctamide N05CM15 Methylpentynol N05CM16 Niaprazine N05CM18 Dexmedetomidine N05CM20 Diphenhydramine N05CM22 Promethazine N05CM25 Magnesium aspartate hydrobromide N05CM26 Magnesium glutamate hydrobromide N05CM27 Doxylamine

=== Pyrimidine derivatives === Pazopanib is a multi-targeted tyrosine kinase receptor inhibitor. The structure is formed by indazole, pyrimidine and a benzene ring. If the indazole ring is kept the same, replacing 5-amino-2-methylbenzenesulfonamide with another arylamine at position 2 of the pyrimidine, gives inhibitory effect on VEGFR-2 and c-Kit. For R2, two groups can show this effect on the compound, an ether group on one, and on the other a chloride group. When substituents are added on pazopanib with different electronic effects at the benzene ring the inhibition to the kinase changes. Regarding the steric effect on position R1 and R2, a hydrogen in position R1 and a trifluoro-ether in R2 have the most inhibitory effect on VEGFR-2, which can be the effect of the electronegative groups. There is a steric hindrance of the indazole heterocycle, which can play an important role in the interaction with the tyrosine kinase receptor inhibition.

Enobosarm, also formerly known as ostarine and by the developmental code names GTx-024, MK-2866, and S-22, is a selective androgen receptor modulator (SARM) which is under development for the treatment of androgen receptor-positive breast cancer in women and for improvement of body composition (e.g., prevention of muscle loss) in people taking GLP-1 receptor agonists like semaglutide. It was also under development for a variety of other indications, including treatment of cachexia, Duchenne muscular dystrophy, muscle atrophy or sarcopenia, and stress urinary incontinence, but development for all other uses has been discontinued. Enobosarm was evaluated for the treatment of muscle wasting related to cancer in late-stage clinical trials, and the drug improved lean body mass in these trials, but it was not effective in improving muscle strength. As a result, enobosarm was not approved and development for this use was terminated. Enobosarm is taken by mouth. Known possible side effects of enobosarm include headache, fatigue, anemia, nausea, diarrhea, back pain, adverse lipid changes like decreased high-density lipoprotein (HDL) cholesterol levels, changes in sex hormone concentrations like decreased testosterone levels, elevated liver enzymes, and liver toxicity, among others. The potential masculinizing effects of enobosarm, for instance in women, have largely not been evaluated and are unknown. The potential adverse effects and risks of high doses of enobosarm are also unknown.

Sources: en.wikipedia.org

Further detail

Hadacidin, and hadacidin analogues, have anticancer activity and activity against adenylosuccinate synthetase. Hadacidin is the simplest known naturally occurring hydroxamic acid. The hydroxylamino group is frequently donated by a hydroxylamino acid such as 8-N-hydroxyornithine of the siderochromes. This compound, first isolated and characterized by Kaczka et al. in 1962, seemed well suited for a study of the route of hydroxamic acid biosynthesis. The hydroxamate bond may be considered to be a peptide bond with an oxygen atom on the amide nitrogen, but there is no a priori reason to decide whether the oxygen atom is introduced before or after the formation of the amide bond. In the latter case, formylglycine would be an intermediate in hadacidin biosynthesis. N-Hydroxylation of an amide bond was reported by Cramer et al. (1960), who found that N-hydroxy-2-acetylaminofluorene was formed in the intact rat upon administration of 2-acetylaminofluorene. Nevertheless, this finding cannot be considered direct proof of N-hydroxylation of an amide bond because, as the authors point out, the acetyl group is labile in their experiments, and hydroxylation of the amino group might have occurred. Glycine, formate, and the 2-carbon of serine were all found to be very quickly incorporated into hadacidin during its synthesis by Penicillium aurantioviolaceum.

Bronchiolitis obliterans is often diagnosed based on the symptoms of obstructive lung disease following lung injury. The definitive diagnosis is through biopsy, but due to the variable distribution of lesions, leading to falsely negative tests, and invasive nature of this procedure it is often not performed. Several tests are often needed to diagnose bronchiolitis obliterans, including spirometry, diffusing capacity of the lung tests (DLCO), lung volume tests, chest X-rays, high-resolution CT (HRCT), and lung biopsy.

=== Se–So === Michael Sela (1924–2022). Israeli immunologist at the Weizmann Institute, who worked on synthetic antigens, molecules that trigger the immune system to attack. Foreign associate Natl. Acad. Sci. USA. Nathan Sharon (1925–2011). Israeli biochemist at the Weizmann Institute of Science, expert on carbohydrates and glycoproteins. Member of the Israel Academy of Sciences and Humanities. Anatoly Sharpenak (1895–1969). Russian biochemist at the Russian Academy of Medical Sciences, who studied protein metabolism, and the aetiology and pathogenesis of dental caries. Sofia Simmonds (1917–2007). American biochemist at Yale known for work on amino acid and peptide metabolism. Karl Slotta (1895–1987). German-American biochemist at the University of Miami who discovered progesterone and studied snake venoms. Emil L. Smith (1911–2009). American protein chemist at UCLA, known in particular for studies of protein evolution. Member Natl. Acad. Sci. USA. Michael Smith (1932–2000), Canadian biochemist at the University of Wisconsin–Madison. Nobel Prize in Chemistry for developing site-directed mutagenesis Oliver Smithies FRS (foreign associate) (1925–2017). British-American geneticist and physical biochemist at the University of North Carolina at Chapel Hill who introduced starch as a medium for gel electrophoresis. Nobel Prize in Physiology or Medicine in 2007. Liz Specht (21st century). American research scientist specializing in chemical engineering and synthetic biology Alberto Sols (1917–1989). Spanish biochemist at the Spanish National Research Council.

Sources: en.wikipedia.org

Frequently asked questions

What receptors does tirzepatide target?

It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.

How does albumin binding affect tirzepatide?

A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.

When was tirzepatide first approved?

The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.

固体粉末应如何存放?

建议在低温、避光、干燥环境中密封保存,常见条件为 2 至 8 摄氏度,长期存放可置于更低温度。应避免反复冻融,并尽量减少容器开启次数。

Network